AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.

伊利诺伊州北芝加哥 - 艾伯维公司（纽约证券交易所代码：ABBV）和Gedeon Richter Plc.宣布达成协议，共同发现和开发治疗神经精神疾病的新疗法。这项合作建立在近20年的合作伙伴关系基础之上，该合作关系已经产生了中枢神经系统疗法，包括cariprazine（VRAYLAR® / REAGILA®）和研究中的药物ABBV-932。

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...

神经科学领域的研究一直是医学界的重要方向之一，它涵盖了对退行性疾病（如阿尔茨海默病和帕金森病）、癫痫、抑郁症、偏头痛、疼痛管理以及众多罕见疾病药物开发。

上证报中国证券网讯（记者 何昕怡）10月17日，艾伯维宣布，美国食品药品监督管理局（FDA）已批准其Vyalev（ABBV-951）上市，用于治疗晚期帕金森病成人患者的运动能力波动。据悉，这是FDA批准的首款基于左旋多巴的24小时皮下连续输注疗法。

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.